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ARTICLE
Structures of insect Imp-L2 suggest an alternative
strategy for regulating the bioavailability of
insulin-like hormones
Nikolaj Kulahin Roed 1, Cristina M. Viola2, Ole Kristensen 3, Gerd Schluckebier 1, Mathias Norrman1,
Waseem Sajid1, John D. Wade 4,5, Asser Sloth Andersen 1, Claus Kristensen 6, Timothy R. Ganderton2,
Johan P. Turkenburg 2, Pierre De Meyts 1,7 & Andrzej M. Brzozowski 2
The insulin/insulin-like growth factor signalling axis is an evolutionary ancient and highly
conserved hormonal system involved in the regulation of metabolism, growth and lifespan in
animals. Human insulin is stored in the pancreas, while insulin-like growth factor-1 (IGF-1) is
maintained in blood in complexes with IGF-binding proteins (IGFBP1–6). Insect insulin-like
polypeptide binding proteins (IBPs) have been considered as IGFBP-like structural and
functional homologues. Here, we report structures of the Drosophila IBP Imp-L2 in its free
form and bound to Drosophila insulin-like peptide 5 and human IGF-1. Imp-L2 contains two
immunoglobulin-like fold domains and its architecture is unrelated to human IGFBPs, sug-
gesting a distinct strategy for bioavailability regulation of insulin-like hormones. Similar
hormone binding modes may exist in other insect vectors, as the IBP sequences are highly
conserved. Therefore, these ﬁndings may open research routes towards a rational inter-
ference of transmission of diseases such as malaria, dengue and yellow fevers.
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The insulin/insulin-like growth factor system is an evolu-tionarily ancient, highly conserved, endocrine and para-crine signal transduction network in multicellular
organisms1. It regulates a broad spectrum of key life processes
such as organism metabolism, somatic growth, development,
reproduction and lifespan, and cell growth, differentiation and
migration at the cellular level. In humans and many vertebrates,
insulin is stored in oligomeric forms in pancreatic β-cells, and is
acutely secreted in response to glucose and nutrients2. It circu-
lates freely in the blood after secretion with a short (~4 min) half-
life3. In contrast, human insulin-like growth factors (hIGF-1 and
2) are secreted by multiple tissues and do not oligomerise but are
tightly bound in biological ﬂuids by several IGF binding proteins
(IGFBP1–6)4–6. Ultimately, insulin and IGFs exert their signalling
through closely related tyrosine kinase type insulin and IGF-1
receptors (IR, IGF-1R)1,7,8(Fig. 1).
The occurrence of similar insulin/IGFs-like hormones (insulin-
like proteins, ILPs), is very diverse in the animal kingdom, ran-
ging from one insulin and IGF-1/IGF-2 in human, eight ILPs in
Drosophila (DILP1–8), to 40 ILPs in C. elegans1,7,9–13. Never-
theless, they share similar motifs of inter-/intra-chain disulphide
bridges and organisation into B, C, A and D-domains, typical of
insulin, pro-insulin and IGF-1/2 (Fig. 2, Supplementary Figure 1).
The variety of types of ILPs is not reﬂected in the number of their
receptors that is limited to one insulin receptor (IR, with IR-A
and IR-B isoforms) and one IGF receptor (IGF-1R) in humans, to
one IR-like in most invertebrates, including insects such as
Drosophila (dmIR)1,7.
The intracellular ILPs-signalling pathways—so called insulin/
IGF axis—are well conserved in the animal kingdom14, in contrast
to the diverse regulations of bioavailability of these hormones. In
humans, this involves six blood-circulating IGFBPs and the non-
signalling IGF-2/mannose-6-phosphate receptor (IGF-2R)15–20
(Fig. 1). The ~213–289 amino acids long, three-domains human
IGFBP-1-6 tightly regulate the level of free IGF-1/2 by forming
binary/ternary complexes with these hormones4–6,16,17,19–21.
An understanding of IGFBP-1–6 was further convoluted by a
proposed extension of the IGFBP superfamily by a number of
cysteine-rich proteins17, which homology to IGFBP1-6 is limited
to their N-terminal IGFBP-like domain, with suggested IGFs
afﬁnities ~100× lower than of the true IGFBPs. These proteins
were termed as IGFBP-related proteins (IGFBP-rPs)17, and they
included Mac25 (temporarily renamed also as IGFBP-7), which
cDNA was originally identiﬁed in meningioma22,23.
Subsequently, it was reported that the cells from the Fall
armyworm, Spodoptera frugiperda, used in baculovirus Mac25
expression secrete a binding protein, named Sf ILPs binding
protein (Sf-IBP), that can bind human insulin, IGF-1 and IGF-
224,25, with high nM afﬁnities, and that it can interfere with the
formation of human insulin:IR complex and its signalling25.
These and other ﬁndings26 revealed that the postulated IGF-
binding properties of Mac25 actually resulted from the con-
tamination of the expression media by Spodoptera endogenous Sf-
IBP, being confused further by similar ~27 kDa molecular masses
of these proteins. As the other members of the purported IGFBP-
rPs family also failed to show any insulin/IGFs binding27,28, there
is now a common consensus that only the six classical, human
IGFBPs-1–6 should be designated as IGFBPs5, and that Sf-IBP
may represent a distinct ILP-bioavailability regulating system
(Fig. 1),
The cloning of Sf-IBP indicated its high homology to the 242
amino acid Drosophila imaginal morphogenesis protein-late 2
protein (Imp-L2)25 that is expressed during imaginal discs mor-
phogenesis29. The secretion of Imp-L2 is induced by 20-hydro-
xyecdysone, and is implicated in neural and ectodermal
development in Drosophila30, with Imp-L2 null progeny from
Imp-L2 null mothers, showing 100% lethality30. Imp-L2 can bind
human IGF-1, IGF-2, insulin, and DILP5 with nM afﬁnities25, it
counteracts insulin signalling in Drosophila being essential for
resistance to starvation, while its overexpression leads to an
extension of the lifespan31,32.
Therefore the aim of this work was to provide the structural
insight into the invertebrate ILPs-regulatory IBPs-based system,
and to assess its molecular relationship to human IGFBPs. Here,
we report the crystal structures of the Drosophila Imp-L2 protein
in its apo-form, and in holo-complexes with insect DILP5 and
human IGF-1. They are supported by ITC and surface plasmon
resonance (SPR) Imp-L2 binding data with human insulin, IGF-1,
and DILP5, and size exclusion chromatography with multi-angle
light scattering (SEC-MALS) and small-angle X-ray scattering
(SAXS) in solution studies of oligomeric states of this protein.
The three-dimensional characterisation of the Imp-L2 IBP in
its free and hormone-complex forms revealed its fold and
hormone-binding mode that are entirely different from, and
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Fig. 1 The main molecular steps in the insulin/IGF axes. IR-A, IR-B isoforms of the insulin receptor (IR), IGF-1R IGF receptor, and their heterodimers, IGF-2R
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unrelated to, IGFBP-1-6. Hence Imp-L2 and, likely, other insects
IBPs, represent an alternative macromolecular system for the
control of the bioavailability of insulin-like hormones.
Results
Structure of apo-Imp-L2. The apo-Imp-L2 consists of two,
similar, immunoglobulin-(Ig)-like fold domains, each of them
with two-sandwiched layers of ~6–7 anti-parallel β-strands. They
contribute to an extensive, continuous β-sheet on the top-side of
the Imp-L2 that is referred here as to inter-domain-β-sheet (id-β-
sheet) (Fig. 3a). The N-terminal Ig-domain (1–142, referred here
as to Ig-NT) is fused by a short linker to the C-terminal
(145–242) domain (Ig-CT) (Fig. 3a). Although both domains can
be classiﬁed as variants of the intermediate (I-set) subfamily of
the Ig-fold they show signiﬁcant variations from this structural
motif, which likely reﬂects its adaptation to a novel organisation
and function of the Imp-L2 (Fig. 3b).
The β-strands of Ig-NT domain consist of two β-sheets: βA
′-βG-βF-βC and βA-βB-βE which generally follow the I-set fold
(Fig. 3a, b)33, but the I-set Ig typical βC′- and βD-strands are
missing in the Ig-NT. Instead, their corresponding polypeptide
chains form here a long, Imp-L2-characteristic 70–92 loop that
joins directly the βC-strand and βE-strand (Fig. 3a, b). Moreover,
a part of its putative βD-strand is fused with the βE-strand giving
it an extra length that is needed for an effective formation of the
Ig-NT:Ig-CT inter-domain interface. This departure from the
classical I-set fold re-directs the 70–92 loop, which joins βE
strand from a different/opposite direction than seen in Ig I-set
domains (Fig. 3b).
The Ig-CT domain follows the Ig-I fold more closely, with its
βC’-strand and βD-strand being present here. The short βA/βA’-
strands of Ig-I are fused here into one, long βA-strand which
together with the antiparallel βE-strand of the Ig-NT domain,
forms a tight Ig-NT:Ig-CT inter-domain interface (Fig. 3a).
However, this Ig I-set typical split of the βA/βA′ strands is
reﬂected in the Ig-CT domain by a signiﬁcant twist of this long
(147–160) βA-strand. As a result, the N-terminal part of this βA
strand (147–154: referred her as to βAN) belongs to βAN-βB/βB
′-βE-βD β-sheet of the Ig-CT, while the C-terminal part of this
strand (157–160: referred here as to βAC) contributes to the βAC-
βG-βF-βC-βC′ β-sheet of this domain (Fig. 3a, b). The structural
strain of the Ig-CT βA-strand that is probably induced by its
domain-interface function seems to be propagated into the
neighbouring βB-strand of this domain, which is split into two βB
(166–168) and βB′ (170–175) strands; a feature not observed in
the Ig I-set. The distal, very short βC’-strand (187–189) is at a
sharp (>50°) angle to the βAC-βG-βF-βC plane and contributes
poorly to this β-sheet.
The continuous inter-domain-β-sheet (id-β-sheet, top-side of
the Imp-L2 (Fig. 3c) is formed by a tight interface between Ig-NT
βA-βB-βE and Ig-CT βAC-βG-βF-βC-βC′ β-sheets that is
stabilised by hydrogen bonds between parts of Ig-NT βE
(92–99) and Ig-CT βAC (157–160) strands. The relative ﬂatness
of the id-β-sheet surface contrasts with a concave shape of the
opposite (back) side of the Imp-L2, with its only one β−strand
thick apex at the βA: βE inter-domain interface (Fig. 3c).
Despite some structural differences, the overall folds of the Ig-
NT- and CT-domains are similar with an rms difference of 1.45 Å
between their Cα chains, calculated after deletion of the 24–31,
72–93, 133–143 loops in the Ig-NT domain (referred here as to a
core Ig-NTΔ). A unique mirror-like edge-to-edge arrangement of
the Impl-L2 Ig-domains brings close (~4.20 Å) its N-terminal and
C-terminal, which is different than in the classical Ig-proteins
were the N/C-termini are at the opposite ends of the domains,
and which enhances further the planarity of the id-β-sheet.
Relation of Imp-L2 to Ig-fold containing proteins. The overall
structure of the Imp-L2 protein does not have any obvious
structural homologues in the Protein Data Bank (PDB). However,
the Ig-NT and Ig-CT domains are remarkably similar to the M10
domain (M101–99, Supplementary Figure 2) that is the most C-
terminal Ig-I-like subfamily segment of the human giant muscle
protein titin34–37, which is a docking platform for several sarco-
meric binding partners such as obscurin38. The Ig-CT domain
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follows more closely the M10 fold (pdb id: 3q4o and 2y9r,
unpublished), with Cα atoms rms difference of 1.11 and 1.17 Å;
the Ig-NTΔ domain has a slightly higher structural deviation of
~1.59–1.48 Å from these M10 structures.
Most importantly, Imp-L2 does not have any structural
relationship to any IGFBPs (Fig. 3d) and represents a new
protein scaffold for the regulation of bioavailability of the insulin-
like hormones in invertebrates.
Oligomeric states of apo-Imp-L2 in the solid state. There are
two, closely packed apo-Imp-L2 molecules in the crystal asym-
metric unit, raising the question about the functional relevance of
this quaternary structure. The dimer results from top-to-top-side
arrangement of the Imp-L2 proteins related by twofold non-
crystallographic symmetry axis that runs approximately parallel
to βA:βE inter-domain interfaces (Supplementary Figure 3). The
~909 Å2 buried apo-dimer interface involves mostly hydrophobic,
π-cation, and only few hydrogen bonds (e.g. 37Lys −231Asp)
interactions. This dimer engages more the top surfaces of the apo-
Impl2 that are closer to the N- and C-termini of the id-β-sheet.
Structure of the Imp-L2:DILP5 complex. The Imp-L2:DILP5
complex revealed 1:1 Imp-L2:hormone mode of binding (Fig. 4).
Imp-L2:DILP5 complex formation is correlated with the pro-
pensity of Imp-L2 to form a new type of the dimer. The crystal
asymmetric unit contains here two independent, but practically
identical dimers (rms of 1.0 Å), that are entirely different from the
apo-Imp-L2 dimer (discussed further in detail in relation to the
Imp-L2 apo→holo related quaternary transitions).
The hormone:Imp-L2 binding mode is identical in all holo-
Imp-L2 dimers, with the rms differences of 0.68–1.09 Å between
all Imp-L2:DILP5 binary complexes. The overall folds of the holo-
and apo-Imp-L2 also remain similar (~0.83 Å rms between Cα
atoms).
The DILP5 hormone binds to Imp-L2 top id-β-sheet mainly by
its B-helix that is almost perpendicular to the direction of id-β-
strands (Fig. 4a). The helix runs in Ig-CT→Ig-NT direction, and is
mostly engaged with the N- and C-termini part of the id-β surface.
The hormone B-chain α−helix:Imp-L2 β-sheet interactions are
depleted of speciﬁc, tight and directional side-chain:side-chain
contacts, which are mostly of a van der Waals, hydrophobic nature
over ca. ~835Å2 buried interface (Supplementary Table 1). The
Imp-L2 contributes βB-βE:βAC-βG-βF strands to the complex
(mainly Trp32, Met58, Ile93, Leu159, Trp211, Met214, Phe233,
Tyr215), while B-helix side chains are limited here to AlaB9,
MetB13, ValB16, AlaB17. However, there is also more speciﬁc
shape complementarity between DILP5 B-chain and the id-β-sheet
(Fig. 4b) as, for example, hormone MetB13 ﬁlls a hydrophobic
cavity formed by Met58, Trp32, Ile93 and Leu159 of the Imp-L2.
The A-chain of the DILP5 ‘overhangs’ the edge of the id-β-
sheet, contributing (e.g. by PheA16) to some van der Waals-
hydrophobic interaction with Imp-L2 (Fig. 4a, b). The C-end of
hormone A1 helix rests on Trp211, and the CysA9 CO–OH
Tyr235 hydrogen bond (3.3 Å) is a rare directional contact on the
hormone:Imp-L2 interface. However, some possible polar
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interactions cannot be excluded as a positively charged region of
the Imp-L2 consisting of Arg95, Arg97 and Lys156, is in the
proximity of AspB12, which is disordered on the apo-Imp-L2
surface (a summary of hormone:Imp-L2 interaction is provided
in Supplementary Table 1).
Importantly, both the hormone and the Imp-L2 molecule
undergo signiﬁcant structural changes upon formation of their
complex. Firstly, the conformation of the N-terminus of B-chain
(B1–B5) of DLP5 must change, as its extended—so-called T-like
—structure, observed in its free state39 and in some insulins
(Fig. 2a), would clash with the id-β-sheet surface. Although the
terminal B1–B5 main chains of the hormone show varying degree
of disorder in four copies of this complex, there is a strong
indication that they attain more so-called R-like, fully helical,
conformation of the B-helix, observed only in some oligomeric
states of insulin, where they are induced by phenolic-like
ligands40,41 (Fig. 2a). The B19–B23 part of the DILP5 B-chain
retains the conformation of the free hormone but its C-terminal
part is disordered.
The fully helical transition of the B1–B5 terminus of the DILP5
B-chain upon Imp-L2 binding correlates with the reallocation (by
ca. ~4.5 Å) of the hormone A-chain to avoid its clash with the
Imp-L2 surface. Here, the ~3.5 Å move of CysB6 pulls the
CysB6–CysA10 disulphide, and, subsequently, the whole A-chain
towards its steric hindrance-free conformation.
The allosteric effect observed in the complexed hormone is
reciprocated by the structural changes in the Imp-L2. The
positioning of the hormone on the id-β-sheet leads to a greater
separation of the N- and C-termini of the Imp-L2, from ~12 Å in
apo-Imp-L2, to over 20 Å distance between the Cα atoms at sites
30 and 240 (Fig. 4a). The mutual hormone and Imp-L2 structural
adaptations lead to closer contacts of the Imp-L2 236–239 C-
terminal segment and the A12-A18 linker of the A-chain α-
helices of DILP5.
Structure of the human IGF-1:Imp-L2 complex. The human
IGF-1:Imp-L2 complex also reveals a dimer that is very similar to
DILP5:Imp-L2 quaternary arrangement (~0.89 Å rms between Cα
atoms of these complexes), and the overall IGF-1 and DILP5
Imp-L2-binding modes are very similar as well (Fig. 5a). How-
ever, a higher resolution of the X-ray data allowed here an
unambiguous tracing of the IGF-1 Gly1-Cys6 N-terminus that
corresponds to a partially disordered N-end of the DILP5 B-helix.
The IGF-1:Imp-L2 complex conﬁrms the nature of the
hormone:Imp-L2 interactions observed in the DILP5:Imp-L2
complex. Remarkably, the N-terminal part of the IGF-1 (Gly1-
Cys6) attains clearly a previously unseen42,43 α-helical fold, giving
the B-helix of this hormone an R-state like conformation (Fig. 5a,
Supplementary Fig. 4). This long B1–B19 helix is required to
avoid a steric clash of this part of the hormone with the Imp-L2
id-β-sheet surface. The IGF-I R-like state is stabilised by a ﬁrm
anchoring of the hormone Gly1 NH2-terminus onto Imp-L2
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surface by 1Gly-NH2—CO Met214 hydrogen bond (3.2 Å), and
close Van der Waals contacts of IGF-1 Cys6–Cys48 disulphide
with the side chain of Imp-L2 Met214 (Fig. 5b). Hydrogen bonds
between Impl-L2 Asn216 -ND2 and -OE1 Glu9 of IGF-1
augment the conformational stability of this region. Further ﬁrm
locking of the IGF-1 on the Imp-L2 surface results from the
interactions similar to those observed in the DILP5:Imp-L2
complex (Supplementary Table 1). Here, the N-(1–30) and C-
(Pro236-Leu238)-termini of the Imp-L2 move apart, contributing
to the expansion of the id-β-sheet surface by accommodating the
Asp160-Met162 peptide as a more integral part of this β-sheet. A
hydrogen bond between hydroxyl of Tyr235 and peptide carbonyl
of IGF-1 Cys52 is formed in this process as well (Fig. 5b).
However, the end of the IGF-1 B-domain (22–29), the whole C-
domain (Gly30–Gly42), and D-domain (Ala62-Ala71) residues
are untraceable here, being also fully depleted of any stabilizing
crystal contacts.
The R-state of hormone B-helix is correlated with other
signiﬁcant changes in the structure of bound IGF-1. While a
typical T→R transition in human insulin leads to ~1.3 Å change in
the position of CysB7 Cα atom, it doubles to 2.6 Å in IGF-1 for its
corresponding Cys6. Moreover, as the CysB7-CysA7 disulphide
in insulin adjusts easily to R-state α-helix, its hIGF-1 counterpart
—Cys6-Cys48 cystine—isomerises in this transition, pulling Cα
atom of Cys48 by ~2.7 Å, and bringing the whole Cys6–Cys48
bridge into a close contact with the Imp-L2 surface. The other
IGF-1 Cys18–Cys61 disulphide also shifts by ~3.1 Å and
isomerises.
The rearrangements of the disulphides in hIGF-1 that are
induced upon hormone:Imp-L2 binding are propagated further
by dragging the equivalents of the A-chains of the hormone—e.g.
by ~7.5 Å for Leu54—from their free-hormone conformation
(Supplementary Figure 4). All these changes give a curvature to
the B-helix, especially around its Phe16-Arg21 region (Fig. 5a).
The importance of the Imp-L2 C-terminus (235–242) in
insulin-like hormone binding is even more evident in the hIGF-1:
Imp-L2 complex, in which the 51–53 linker of the hIGF-1 A-
helices is hydrogen-bonded to the Imp-L2 by 52Cys CO-HN
Leu238 (2.8 Å), and Ser51 OG-OC Pro236 (2.9 Å) interactions.
Imp-L2 apo-holo quaternary transitions in crystal structures.
Although the separation of the N- and C-termini of the Imp-L2
upon binding of both DILP5 and IGF-1 is clear, and required for
its effective engagement with these hormones, the largest rear-
rangement of the Imp-L2 tertiary structure upon apo→holo
transition is associated with the formation of its new dimer. Here,
the apo-Imp-L2 top-to-top surface dimer (Supplementary Fig-
ure 3) is replaced by a much tighter back-to-back dimer (~1670
Å2 buried surface), with almost perpendicular directions of the
β-strands in the adjacent monomers (Fig. 6a).
The pressure of hormone A chain on the Imp-L2 C-terminus
drives it away from its N-terminal end, priming in this process
the Imp-L2 237–242 region for direct interactions with the
hormone (Figs. 4a, 5a). Subsequently, the 1–16 part of the Imp-L2
N-terminus must move, pushing the adjacent 84–91 part of the
70–90 loop to accommodate the incoming A chains of the
hormones. This, likely, triggers a large sway of the whole 60–91
loop, facilitating in this process a holo-dimerisation of the Imp-L2
that is different from its apo-dimer. Therefore, the swing of the
70–92 loop is one the key features of the apo→holo Imp-L2
transition, as this βC- and βE-strand joining protein chain that
runs outside the βA-βE edge of the apo-Ig-NT domain, folds now
onto the back-surface of the holo-Imp-L2 (Fig. 6b, c). However,
the 70–90 loop does not stick to the back-surface of its parental
Imp-L2 molecule, but is tethered into its dimeric partner
molecule, running close to its βE:βB’-βC strands surface (Figs. 4a,
6b, c). This remarkable displacement of the 70–90 loop is
exempliﬁed by over 20 Å distance between the apo-/holo-Cα
atoms of Asp78. The interface of the monomer-A-loop:mono-
mer-B-bottom surface has a mixed hydrophobic/hydrophilic
character, with only few hydrogen bonds, such as Arg74CO-NE2-
His104 (3.4 Å), Leu80 NH-CO Val172 (2.38 Å), and Asp79 OD1-
NH Val172 (3.35 Å).
Imp-L2 self-association in solution. The dynamics of the
apo→holo Imp-L2 oligomeric transitions in solution was assessed
by SEC-MALLS analysis and SAXS. In contrast to crystal-
observed holo-dimerization of the Imp-L2, the addition of DILP5,
insulin X14 and IGF-1 showed apo-dimer→holo-monomer phe-
nomena in SEC-MALLS experiment (Supplementary Figure 5).
As insect metamorphosis is associated with osmotic variability of
the hemolymph44,45 the quaternary behaviour of apo-Imp-L2 was
also monitored by SEC-MALLS at different ionic strengths
(Supplementary Figure 6). Here, the apo-Imp-L2 remained
dimeric at 50 mM NaCl, formed mixed dimer/monomer popu-
lations at 150 mM NaCl, becoming prevalently monomeric at 300
mM NaCl.
The in-solution dynamic nature of the Imp-L2 was assessed
further by SAXS. It conﬁrmed that the Imp-L2 solutions were not
monodisperse, with apo-Imp-L2 showing a higher apparent
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Fig. 6 Organisation of the holo-Imp-L2 dimer in complexes with DILP5 and IGF-1. Only DILP5 complex is shown as a representative example. Each
individual Imp-L2 molecule is in white and yellow, DILP5 B-chain in green and A-chain in blue. a The general arrangement of the holo-dimer in a view
similar to as in Fig. 3a and 4a. b A close-up on the inter-monomer interface in holo-dimer after ~90° rotation along horizontal axis of the dimer shown in a.
c A close-up on the inter-monomer interface in holo-dimer after 90° rotation along vertical axis of the dimer shown in a. The 70–92 loops of each dimer
shown in Van der Waals spheres, and coloured correspondingly to their monomers
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radius of gyration Rg than its hormone complex, in agreement
with the SEC-MALLS data (Supplementary Figure 7). These
suggest either a change in the oligomeric state—e.g. dimer to
monomer—upon the apo→holo Imp-L2 transition, or a compac-
tion of the Imp-L2 structure upon ligand binding.
Imp-L2 hormone binding. Although our previous DILP5:Imp-
L2-binding assay showed high-afﬁnity interaction between these
proteins39, the precise Kd of this interaction was not derived there
due to a high variation of the measurements and some high non-
speciﬁc binding characteristic of the used polyethylene glycol
(PEG) 8000 radioactive ligands assay. Hence, the Kd of the DILP5
was assessed here by isothermal titration calorimetry (ITC), and
was also repeated by ITC for insulin and IGF-1, to assure some
comparability of the Kds of these hormones (Table 1, Supple-
mentary Figure 8). Despite some differences resulting from the
unrelated natures of PEG and ITC methodologies both types of
assays showed similar ranges and trends of hormone:Imp-L2
interactions. As expected, DILP5 is the strongest binder in the
ITC assay—8 nM, followed by IGF-1–13.6 nM, and insulin—135
nM.
Interestingly, thermodynamic proﬁles of these ITC data
revealed different thermodynamic sub-processes that drive
hormone:Imp-L2 binding (Supplementary Figure 9). In contrast
to a prevalently enthalpic aspect of DILP5, IGF-1—Imp-L2
associations, insulin interaction with Imp-L2 shows large entropic
component, which may indicate substantial, structurally challen-
ging rearrangements on the hormone side.
To account for the variability of the ionic strength during
insect metamorphosis44,45 DILP5:Imp-L2 binding was also
measured as a function of salt concentration (Supplementary
Figure 10). Remarkably, the low 50 mM NaCl concentration has
an inhibitory effect on hormone binding, while the high—300
mM—salt concentration shifts DILP5 Kd from ~8 nM into ~5 pM
range.
Finally, the ITC binding studies were complemented by SPR
analysis of hormone:Imp-L2 interactions. All four hormones:
human insulin and IGF-1, DILP2 and DILP5 bound to the
immobilized Imp-L2, albeit with different binding kinetics
(Supplementary Figure 11). However, their complex SPR
characteristics did not allow ﬁtting of the appropriate Kds.
Nevertheless, the SPR data conﬁrmed the functionality of all
protein components. The amount of the hormones remaining in
the complexes with the immobilized Imp-L2 indicate higher
DILP5 and DILP2 afﬁnities (in a nM range) than human insulin
and IGF-1, in agreement with our previous and current binding
data.
Discussion
The Imp-L2 protein represent an alternative paradigm in the
molecular control of biological actions of insulin-like hormones.
Both the Imp-L2 structure and its hormone binding modes show
no relation to any of the human IGFBPs. Although the Ig-NT-
domain and CT-domain of the Imp-L2 resembles Ig-I fold with
similarity to M10 domain of human muscle protein titin, the
overall arrangement of these domains, hence the overall structure
of the Imp-L2, is different.
The apo→holo-transition of the Imp-L2 allows comparing its
hormone binding mechanism to a molecular mouse trap. The
hormone approaches the dimeric Imp-L2 trap, sensing the bait in
the form of its closely located N-/C-termini (1–26, 237–242,
respectively). The subsequent push of the hormone A chain-
helices 51–54 linker region on the bait drives the Imp-L2 N-/C-
termini apart, triggering the release of the spring of the trap in the
form of 70–92 loop, which then moves onto the back side of the
Imp-L2, and can stablise a new type of dimer such as observed in
the crystal state.
The importance of the C-terminal region in hormone binding
is corroborated by Ala-scanning of this very conserved region in
Imp-L2 homologous Sf IBP (see Fig. 7 below), where Ala-
substitutions of Phe234 (Imp-L2 Phe233), Tyr236 (Tyr235) and
Pro237 (Pro236) reduce hormone afﬁnities of the Sf IBP >5
fold46.
The mechanism of Imp-L2-mediated immobilisation of the
ILPs is very different from the human IGF:IGFBPs-binding mode,
where a tight hormone binding is assured by the cooperation of
the ﬂexibly-linked, cleft-like N- and C-terminal domains of the
IGFBPs (Fig. 3d), into which a wedge-shaped IGF is tethered via
its ‘edge’ B-helix. In contrast, the Imp-L2 hormone binding is
fulﬁlled by a straight accommodation of the IGF-1/DILP5 B-helix
across the inter-domain β-sheet, and a large swing of the Imp-L2
70–92 loop that facilitates new dimeric quaternary arrangement
of the two Impl-L2 in the crystal.
Interestingly, DILP5 afﬁnity for the Imp-L2 is strongly ionic-
strength dependent, shifting from ~8 nM at 150 mM NaCl, to
~1 pM at 300 mM NaCl. While the ITC method can be erratic
at a sub-nanomolar binding range, it is, nevertheless, rather
clear that DILP5:Imp-L2 afﬁnity is signiﬁcantly enhanced at
high ionic strength. However, it remains unclear whether this
afﬁnity shift results from high ionic strength→monomeric Imp-
L2 effect—hence higher exposition of hormone binding surface
that is obstructed in the apo-dimer, or whether it reﬂects a
physiological role of the DILP5/Imp-L2 in insects. Ecdysis, the
process of shedding the outer cuticle in insects metamorphosis,
is stimulated by 20-hydroxyecdysone, which induces the Imp-
L2 gene (29–30), and is paralleled by increase of the osmolarity
of the moulting ﬂuid/hemolymph44,45. Further investigation of
Imp-L2 involvement in ecdysis is required to assess the phy-
siological reasons behind its variable afﬁnity to DILP5 observed
in vitro.
There are discrepancies between ﬁrmly packed holo-Imp-L2
dimers that are observed in the crystal state, and the monomeric
forms of the Imp-L2 complexes that dominate solutions of this
protein in vitro. It cannot be excluded that the mono-
mer↔oligomer equilibria may be shifted towards dimers upon
crystallization by high Imp-L2 concentrations used during this
process. Nevertheless, a tight nature of the holo-Imp-L2 dimers, a
possible inter-molecular cross-bridging role of the 70–90 loop, the
rearrangement of which is associated with other pronounced
hormone-induced structural changes in the Imp-L2, and, ﬁnally,
a higher salt crystallization environment that, according to the
SEC-MALLS results, should assure a more monomeric popula-
tion of Imp-L2, may still suggest some physiological relevance of
its alternative dimerisation.
Table 1 Hormone binding data for Imp-L2 and other putative
IBPs from Spodoptera frugiperda (Sf-IBP) and Trichoplusia ni
(Tn-IBP)
Dm Imp-L2 Sf-IBPb Tn-IBPb
Insulin X14 135(±16)a/81b 0.07 0.02
Proinsulin nm /87b 0.02 0.01
IGF-1 13.6(±4) a/17b 0.17 45
IGF-2 nm/42b 0.37 194
DILP5 8.0(±1)a/nm nc nc
nc not calculated to due variability of the measurements, nm not measured, (±) standard
deviation of the ITC measurements
aIndicates Kd values determined in this work by isothermal titration calorimetry (ITC)
bIndicates afﬁnities (EC50) measured by PEG assay in our previous work25 (all in nM). The Sf-
IBP and Imp-L2 proteins were obtained in ref. 25 from conditioned medium from BHK cells
overexpressing these proteins, and Tn-IBP was from conditioned medium from Trichoplusia ni
HI5 cells. Insulin fully monomeric X14 (ProB28Asp) mutant was used for the ITC
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An overall high sequence identity (33%) between Sf IBP and
Dm Imp-L2 (Fig. 747), especially >60% in the C-terminal
~200–240 hormone-binding regions (Supplementary Figure 12),
suggests that their overall folds and hormone binding modes may
be similar, and be representative of other members of insect IBP
family. Therefore the differences in speciﬁcity of hormone
binding (e.g. insulin vs. IGF-1) between Sf IBP and Imp-L2
(Table 1) may originate from more subtle side chain differences
in some speciﬁc/complementary regions of IBPs and hormones,
rather than from their very different tertiary structures; an ease of
attainment of the R-conformation by the N-termini of the hor-
mones can play a role here as well (see below).
The analysis of emerging genomic data, especially from data-
bases for blood feeding insect vectors48 indicate a presence of
similar Imp-L2-like IBPs in insects. For example, Imp-L2
sequence has a high (>38%) identity with putative IBPs of
Aedes aegypti, Anopheles darlingi and Culex quinquefasciatus
mosquitos, that are responsible for spread, among others, of the
dengue, zika and yellow fevers (Fig. 7, Supplementary Figure 12).
Such high sequence similarity, particularly within C-terminal
region of the IBPs (>40%) that is responsible for the Imp-L2:
hormone interactions, suggests possible similar fold and hormone
binding mode within a broader family of insects IBPs. This is of
both fundamental and bio-medical signiﬁcance in the light of
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Fig. 7 Sequence alignment of some representative and putative IBPs. Sequence numbering as for the Imp-L2 structure; key residues for hormone binding
observed in the holo-Imp-L2 structures are indicated by stars in magenta, while residues that lowered Sf-IBP hormone afﬁnity more than ﬁve times in Ala
scanning experiment are marked by black stars. dm D. melanogaster Imp-L2, ad Anopheles darlingi, aa Aedes aegypti, cq Culex quinquefasciatus, sf Spodoptera
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06192-3
8 NATURE COMMUNICATIONS |  (2018) 9:3860 | DOI: 10.1038/s41467-018-06192-3 | www.nature.com/naturecommunications
growing evidences about the role of ILPs in the blood-feeding-
host:pathogen interactions49, which add human hormones into a
currently binary insect-vector:pathogen relationship. It seems that
human insulin and IGF-1/2 present in the blood-meal ingested by
an insect vector have hormone-speciﬁc effects on both the vector
and pathogen physiology (e.g.50–54), as IGF-1, in contrast to
insulin, extends the lifespan of mosquito Anopheles stephensi, also
enhancing the resistance of this vector to P. falciparum55.
Therefore, the Imp-L2:hormones complexes reported here pro-
vide the structural insight into a possible nature of some com-
ponents of such complex cross-species human hormone:vector:
parasite inter-relations. The lack of analogous, IBP-like, hormone
control in humans makes it tempting to also probe this system to
modulate vector biology in order to reduce, or block, parasite
transmission.
Moreover, it would be interesting to expand the studies on
IBPs on other ILPs-dependent invertebrates such as C. elegans
and roundworm Trichinella britori, as they may use Imp-L2-like
proteins, or similar structural modules, for their development and
physiology (Fig. 7). The analysis of the available genomes suggests
the extension of the previously postulated TFxYP (~242–246
(Imp-L2 numbering) signature sequence of Imp-L2 and Sf-IBP46
for at least two other in the C-terminal hormone binding region
of the IBPs: G-(D/E)-L-alkyl-I (~202–206), and WxDMGxYxC-
(I/V)-A-(R/K)-N (~214–222) (in brackets: alternative residues in
this position) (Fig. 7).
The Imp-L2 structures expand the already abundant super-
family of the Ig-fold—the most coded metazoan module56—with
further structural variations and functional application. The
fusion of two Ig-domains in Imp-L2, and, possibly, in other
insects IBPs, is different from similar motives found in even
structurally very related human muscle protein titin M10 domain,
and its complexes that rely on extensive Ig–Ig domain interac-
tions. Their head-to-tail arrangement in M10 complexes, likely
dictated by the directionality of these ﬁlaments in the muscle M-
band, is different from the Imp-L2 mirror-image-like Ig-NT:Ig-
CT fold.
The complexes of Imp-L2 revealed also a full B-helix R-state of
the insulin-like hormones, which was considered to be limited to
possible storage, or non-physiological, forms of human insulin,
and it was never observed (or postulated) in IGF-1/2, nor in the
known complexes of these hormones with IR. Here, we show that
sole protein-protein interactions, unlike the insulin organic
ligand-induced ones, are sufﬁcient to facilitate and stabilize a full
(B1–B19) helix formation in IGF-1 and DILP5. The role of
phenolic-like ligands that induce the R-state in human insulin is
fulﬁlled in the Imp-L2 by its inter-domain β-sheet surface. This
demonstrates that the R-state of insulin-like hormones may not
be a structural artefact, but a fold relevant for their physiology.
The high entropic component observed by the ITC in the insulin:
Imp-L2 complex formation correlates also with its lowest afﬁnity
of all hormones measured here. They may reﬂect the resistance of
the required T→R conformational change of insulin B-chain upon
its Imp-L2 binding due to its length, and insulin particular, B1-B6
sequence. Symptomatically, crystallizations of the insulin:Imp-L2
complex were (yet) unsuccessful.
The hIGF-1/DILP5:Imp-L2 complexes also raise a question
about the origins of the modes of insulin-like hormones inter-
actions with their receptors (i.e. IR, IGF-1R, dmIR, etc.). The
structures of insulin and hIGF-1 complexes with so-called site 1
of the IR, that is located at the N-terminal part of the receptor in
the form of the L1-CR domains, show mostly a non-direct hor-
mone binding to L1 β-sheet surface (L1-β2) (Fig. 8b). It is
mediated there by so-called α-CT segment: an α-helical, ~16
amino-acid (704–719) C-terminus of the opposite α-subunit of
the IR, and which is an integral part of site 157. Although the L1
domain and Imp-L2 structures are not easily comparable, they
possess similar, extensive β-sheet surfaces which both proteins
use for the recruitment of an α-helix (Fig. 8a, b). In the Imp-L2 it
is the long (1–19) B-helix of the hormones, while in the IR it is
the α-CT segment of this receptor. As the α-helix:β-sheet inter-
actions are common58, it is interesting why IR (and IGF-1R) L1-
β2 surfaces are not engaged directly with B-helices of the hor-
mones, but the α-helical CT-segments of the receptor(s) are used
as mediatory components of hormone binding. Nevertheless, the
similar mode of α-helix:β-sheet motif of protein:protein interac-
tion in α-CT:IR and Imp-L2:hormone complexes is striking
(Fig. 8), despite its very different functional role and origin. One
of the possible reasons behind the general quaternary con-
vergence but functional divergence of these structures, could be
the incapability of the IR (IGF-1R) L1-β2 surface to induce a fully
α-helical, R-like state of insulin/IGF-1 B-chain/domain that could
be required, as in Imp-L2, for an effective direct binding of the
hormones. Such transition would be especially challenging for
insulin, while shorter N-termini of DILP5 and IGF-1 are more
capable of such structural change (Supplementary Figure 9).
Therefore, the receptor α-CT helical segment must replace the
hormone B-helix and serve as an anchor for the attachment of
hormones to IR and IGF-1R. However, the different modes of
hormone:protein interactions in IBPs and IR/IGF-1R may arise
from many other, more function-related reasons, as, for example,
a non-direct hormone binding to the L1-β2 surfaces of receptors,
facilitates modulation/attenuation of the hormone binding, hence
signal transduction, helping also to maintain the receptors in on/
off states. A complex signalling of the IR-like receptors must
reﬂect the multifaceted regulatory roles of insulin and IGF-1/
IGF-2, and a direct hormone binding to the receptor L1-β2 sur-
face would be too simplistic for this purpose.
In summary, the relevance of structural and functional insights
into apo/holo-Imp-L2: IBP system reported is manyfold. Firstly, it
reveals a β-sheet fold that serves as a direct, high-afﬁnity binder of
these hormones. Secondly, Imp-L2 represents likely an alternative
hormone binding and regulatory IBP system that is different and
evolutionarily independent from human IGFBPs. Moreover, Imp-
L2 shows capability of enforcing an allosteric effect on insulin-like
hormones, inducing R-state conformation of their corresponding
B-chain α-helices, a phenomenon not observed before in any
insulin-like hormones:protein interactions. A similar α-helix:β-
sheet mode of hormone:protein interface that is employed by
both Imp-L2 and IR/IGF-1R, sheds also light on a possible
molecular reasons behind the functional divergence of these two
systems. Finally, a likely structural conservation of Imp-L2 hor-
mone-binding mode in other IBPs in insects and in some other
invertebrates, together with their possible interactions with
human insulin and IGF-1/2 in insect vectors, expands the rele-
vance of these IBPs towards insect-vector associated diseases,
indicating also opportunities for the exploration of other
approaches in pathogen transmission-blocking strategies.
Methods
Production of recombinant proteins. The construct encoding Imp-L2 recombi-
nant protein was made using polymerase chain reaction ampliﬁcation of Droso-
phila Imp-L2 cDNA (Uniprot No: Q09024) available in-house25 for sub-cloning
into the pBac4x vector (Novagen) using the SLIC method59. Brieﬂy, the insert and
backbone fragments were ampliﬁed with 15 base pair complementarity on the 3′
and 5′ ends of each fragment. Baculovirus was produced using the FlashBac
method (Oxford Expression Technologies) and bacmid60 and puriﬁed from the
conditioned media of infected Sf9 cells (primers are listed in Supplementary
Table 2). The recombinant protein consisted of the full-length protein with the
native signal peptide and C-terminal HRV14 3 C proteolytic site (EVLFQGP),
followed by two SR residues and a Strep-tag II (SAWSHPQFEK) sequence. In the
ﬁrst step of the puriﬁcation the buffer was changed to PBS (Invitrogen) by gel-
ﬁltration of 1 L supernatant using an INdEX 100/95 column (GE Healthcare). The
resulting sample was run on a Strep-Tactin column (IBA), and the protein was
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eluted by 2.5 mM desthiobiotin (Sigma-Aldrich) in PBS, with the yield ~ 5 mg/L of
cell culture. The Strep-tag II was removed by available in-house HRV14 3C pro-
tease61. Finally, the gel-ﬁltration with HiLoad 16/60 Superdex 75 prep grade col-
umn (GE Healthcare) were performed to change either into 10 mM HEPES
(Sigma-Aldrich) pH 7.4, 20 mM NaCl (Sigma-Aldrich) crystallization buffer, or
into PBS buffer for further binding/SAXS studies. The selenomethionine-labelled
protein was produced according to Bellizzi et al.62, with the yield ~ 1 mg/L of cell
culture. The complex of Imp-L2 with DILP5 for SAXS experiments was puriﬁed by
running 1 mL mixture of 5 mg of Imp-L2 and 15 mg of DILP5 available in-house39
on a HiLoad 16/60 Superdex 75 prep grade column. N-terminus one amino acid
truncated (B2-B29), expression optimized, so-called C4 variant of DILP539 has
been used throughout this study as it is referred here as DILP5. Human IGF-1 used
for co-crystallization and binding experiments was available in-house (Novo
Nordisk). Synthetic DILP2 for SPR binding experiments was prepared as pre-
viously described63.
Hormone-Imp-L2 binding ITC and SEC-MALS studies. Experiments were carried
out using a MicroCal200 calorimeter (Malvern). Imp-L2 (0.5–0.7 mg/mL) was in
50 mM Tris, 150 mM NaCl, pH 7.4 buffer. Imp-L2 concentration was measured by
UV using an extinction coefﬁcient of E280= 1.25 cm2/mg. Typically, a run con-
sisted of 19 injections of 2 µL into the cell with a 30 s interval between injections.
Duplicates of all experiments were carried out at 25 °C. Imp-L2 concentrations of
12.8–22.6 µM were used with a hormone concentration about tenfold greater. The
concentration of Imp-L2 was adjusted to give c values (c= Ka[Imp-L2], where Ka is
the equilibrium binding constant) between 10 and 500. Very high values of c
(>1000) in the case of DILP5 led to a step-shaped isotherm limiting the accuracy of
the ﬁtted Ka value. Data ﬁtting and analysis were carried out with the manu-
facturer’s software, MicroCal PEAQ-ITC Analysis. The concentration of the
hormones were adjusted so that the stoichiometry of binding was 1:1 given that the
Imp-L2 has a single binding site.
The effects of different ionic strengths on apo-Imp-L2 homodimerization
were investigated by SEC-MALLS as well. In these experiments ligand free 100 µL
Impl-L2 samples at 1 mg/mL in 50 mM Tris, pH 7.4 buffer were incubated in at
50, 150, and 300 mM NaCl and run on a Superdex S200 10/300 gel ﬁltration
column.
The change of the apo- to holo-aggregation of the Imp-L2 upon binding of
DILP5, insulin and IGF-1 was also measured at 150 mM NaCl, 50 mM Tris, pH 7.4,
by SEC-MALLS Superdex S200 10/300 gel ﬁltration column at room temperature.
SPR experiments. Approximately 500 RU of Imp-L2 was immobilized on CM5
chip using amino coupling kit (Biacore/GE Healthcare). The ﬂow speed was set to
50 μl/min. The experiments were performed in PBS buffer (Invitrogen) at 25 C
using T200 Biacore instrument.
Crystallization, crystal structure and SAXS experiments. Crystallization of apo-
Impl-L2 resulted from hanging-drop experiments by mixing 1 μL protein (5.5mg/mL)
and 1 μL reservoir solution (17% w/v PEG 6K, 0.1M Tris/HCl, pH 7.0). The structure
was solved by multiwavelength anomalous dispersion using SHELX software64.
Crystallization of the DILP5:Imp-L2 complex was obtained by mixing equivalent
volumes of protein (10mg/mL, at IMP-L2:DILP5 1:3 molar ratio) and reservoir
solution (8–10% w/v PEG 4K or 6 K, 20mM MgCl2, 0.1M HEPES pH 6.8–7.5).
Crystals of the IGF-1:Imp-L2 complex grew by mixing equivalent volumes of protein
complex (10mg/mL, Imp-L2:IGFI-1 1:3 molar ratio) and reservoir solution (4–8% w/v
PEG 6K, 5–20mM MgCl2, 5mM SB12, 0.1M Tris pH 7.5). All crystallization
experiments were performed at 293 K. All crystals were directly ﬂash-cooled in liquid
N2, X-ray data were collected at 100 K and processed by xia265. The structures of the
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Fig. 8 Comparison of DILP5:Imp-L2 and insulin:IR binding modes. a, b Are the top views on the Imp-L2 and L1 IR surfaces, with shown only the directly
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insulin in IR complex coloured in yellow (B-chain) and green (A-chain). The complexes in d are more in a close-up after ~ 90° rotation of the view in
c along its horizontal axis
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complexes were solved by Molecular Replacement66,67, using the structures of apo-
Imp-L2, DILP5 (C4 version of DILP539), and IGF-1 (PDB ID 1gzr) as models. Model
building and reﬁnement were performed by COOT68 and the CCP4 suite of pro-
grams69. Details of X-ray data collection, and reﬁnement statistics are in Supple-
mentary Table 3, and representative stero images of portions of electron density maps
are shown in Supplementary Figure 13. Figures were made using CCP4mg70.
The SAXS experiments were performed at ESRF Grenoble, beamline ID14-3.
The samples were in PBS buffer (Invitrogen) and SAXS data were recorded at 25 °C
during a 10 × 10 s exposure time on a 1M pixel 2D Pilatus detector (DECTRIS)
covering a q range pf 0.0055−0.609 Å−1 (q= 4πsinθ/λ, where λ is the wavelength
and θ is half the scattering angle). Initial data processing was conducted using
programs from the ATSAS package71.
Data availability
The structures of Imp-L2 and its DILP5 and IGF-1 complexes were deposited in PDB
database under accession codes 4CBP, 6FEY, 6FF3, respectively. SAXS curves and
experimental parameters were deposited with the SASDB (www.sasdb.org) under
accession numbers SASDDS8, and SASDDT8. All other data supporting the ﬁndings of
this study are available from the corresponding author on reasonable request.
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